SOURCE: NeuroPerspective

NeuroPerspective

October 03, 2011 10:51 ET

Alzheimer's Therapeutics Reviewed by NeuroPerspective

CARDIFF, CA--(Marketwire - Oct 3, 2011) - NI Research has released the October issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics, and a critical assessment of the pharma industry's ill-considered allocation of R&D resources to date. While there has been some acknowledgment in the field that the amyloid is, at the very least, an incomplete mechanistic framework, and that tau may constitute a critical downstream component of the neurotoxic process, the flagship pivotal testing programs completed or underway have been amyloid-focused. Other potentially useful mechanistic approaches have often languished for lack of resources. A recalibration of what constitutes a comprehensive AD pipeline is required, which opens the door for therapeutics utilizing other mechanisms, such as those addressing tau, metal-binding, insulin, and neurotrophin-enhancement.

The task of assessing the efficacy of therapeutic candidates has also been complicated by the uncertainty as to when, in addition to where, in the disease-process interventions can be effectively targeted. Some treatment failures may be due to the fact that they were 'too little', but it is also possible that several were 'too late', after irremediable damage has already been done. The hope is that addressing prodromal Alzheimer's, and the use of biomarkers, will allow for intervention when it can make a difference. However, there is at this point no truly validated molecular target, and no clinically proven biomarker for assessing drug effect on disease-progression.

The goal of AD treatment also warrants a reset, as sustaining function farther into the lifespan may be as useful, and more safely viable, than is the elusive goal of disease-modification. Programs which sustain functional autonomy more effectively could emerge from a host of cognitive enhancement targets; including nicotinic and/or muscarinic receptors, AMPA, PDE, mGluRs, 5HT-6, and/or H3 antagonism.

Over 200 therapeutic programs from 125 companies are covered in this review. They include at-risk leviathan programs, like JNJ/Pfizer/Elan's bapineuzumab and Lilly's solanezumab; variations on the secretase theme from Bristol Myers Squibb, EnVivo Pharmaceuticals, Probiodrug, and Neurogenetic Pharmaceuticals; innovative approaches to disease progression from Proteostasis Therapeutics/Elan, Alectos/Merck, reMYND/Roche, and NeuroPhage; and those with early clinical data, such as Targacept (NASDAQ: TRGT) /AstraZeneca, Ceregene, EnVivo Pharmaceuticals, TauRX, and Prana's PBT-2. There are also some companies who have chosen to first pursue Progressive Supranuclear Palsy, hoping that success can then make Alzheimer's a viable focus, such as Allon Therapeutics (TSX: NPC), Mithridion, and Noscira.

The October issue also includes commentary on a premature insistence by some companies for 'validated molecular targets' that do not yet exist ('The Illusion of Certainty'), and BioTie's dramatic expansion via their acquisitions of Synosia Therapeutics and Newron. A brief review of the neurodegeneration company NeuroPhage is also included.

NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development. Recent issues have reviewed therapeutic programs in Autism and Spinal Cord Injury.

A one-year subscription to NeuroPerspective is $2200, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three-month trial subscription is US$700. The October issue of NeuroPerspective is available for $500.

CNS 2011: Therapeutics and Licensing is the 482 page annual overview of all major neurotherapeutics areas and the programs being developed within them. This evaluation also reviews the neurotherapeutics programs and licensing agendas for major and midsize companies in the CNS area. Opportunities for opportunities for licensing and M&A are appraised, as well as trends in financing and deal structure. This provides a vital targeting resource for licensing efforts on both sides of the transaction, potential licensors and licensees.

Samples of a therapeutic area review and pharma licensing section can be downloaded from http://www.niresearch.com/NewPublications.html

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective/NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing, an annual compendium of all CNS R&D programs, since 2007.

NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.

Contact Information